Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest Update

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) was the target of a large decline in short interest in the month of June. As of June 15th, there was short interest totalling 500 shares, a decline of 87.8% from the May 31st total of 4,100 shares. Based on an average trading volume of 290,100 shares, the short-interest ratio is presently 0.0 days.

Provectus Biopharmaceuticals Stock Performance

OTCMKTS PVCT traded down $0.01 on Friday, hitting $0.13. 319,198 shares of the company’s stock traded hands, compared to its average volume of 112,411. Provectus Biopharmaceuticals has a 1-year low of $0.06 and a 1-year high of $0.22. The firm’s 50-day moving average price is $0.18 and its two-hundred day moving average price is $0.15.

Provectus Biopharmaceuticals Company Profile

Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.